Price Action to Note: Zafgen Inc Can’t Be More Safe. Trades Significantly Higher

Price Action to Note: Zafgen Inc Can't Be More Safe. Trades Significantly Higher

The stock of Zafgen Inc (NASDAQ:ZFGN) is a huge mover today! About 155,841 shares traded hands. Zafgen Inc (NASDAQ:ZFGN) has declined 50.29% since April 18, 2016 and is downtrending. It has underperformed by 54.72% the S&P500.
The move comes after 5 months positive chart setup for the $97.29M company. It was reported on Nov, 18 by Barchart.com. We have $7.72 PT which if reached, will make NASDAQ:ZFGN worth $111.88M more.

Zafgen Inc (NASDAQ:ZFGN) Ratings Coverage

Out of 8 analysts covering Zafgen Inc (NASDAQ:ZFGN), 1 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 13% are positive. Zafgen Inc has been the topic of 16 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The rating was downgraded by FBR Capital to “Mkt Perform” on Wednesday, July 20. The stock has “Buy” rating given by SunTrust on Monday, October 19. The stock of Zafgen Inc (NASDAQ:ZFGN) has “Market Perform” rating given on Wednesday, July 20 by Cowen & Co. The company was upgraded on Thursday, January 21 by RBC Capital Markets. Canaccord Genuity maintained Zafgen Inc (NASDAQ:ZFGN) rating on Friday, November 13. Canaccord Genuity has “Buy” rating and $30.0 price target. JMP Securities downgraded the stock to “Mkt Perform” rating in Monday, October 19 report. The firm has “Sector Perform” rating by RBC Capital Markets given on Wednesday, December 2. The stock of Zafgen Inc (NASDAQ:ZFGN) earned “Outperform” rating by FBR Capital on Thursday, January 21. The stock of Zafgen Inc (NASDAQ:ZFGN) earned “Neutral” rating by Suntrust Robinson on Thursday, December 3. The stock of Zafgen Inc (NASDAQ:ZFGN) has “Hold” rating given on Thursday, March 10 by Canaccord Genuity.

According to Zacks Investment Research, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts.”

More notable recent Zafgen Inc (NASDAQ:ZFGN) news were published by: Marketwatch.com which released: “Zafgen shares drop more than 40% as drug focus shifted” on July 19, 2016, also Marketwatch.com with their article: “/quotes/zigman/3870025/realtime” published on June 19, 2014, Wsj.com published: “Zafgen’s Halted Obesity Treatment Shows Effectiveness” on January 20, 2016. More interesting news about Zafgen Inc (NASDAQ:ZFGN) were released by: Bloomberg.com and their article: “Zafgen Obesity Drug Trial on Hold After Second Patient Death” published on December 02, 2015 as well as Prnewswire.com‘s news article titled: “Zafgen, Inc. and Its CEO Sued for Securities Fraud” with publication date: October 21, 2015.

ZFGN Company Profile

Zafgen, Inc., incorporated on November 22, 2005, is a biopharmaceutical company. The Firm is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment